Medication info
Levomos 2.5/20 mg

Levomos 2.5/20 mg

Prescription medicationTabletOral
Ingredient · strength
Olmesartan Medoxomil›20mg / 1 tabletS-Amlodipine Besylate 2.5 Hydrate›3.74mg / 1 tablet
Manufacturer / importer
Anguk Pharmaceutical Co., Ltd.
Appearance
White round film-coated tablet
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 201405841 · Approved 2014.12.10 · Insurance code 650204250

Summary

Main use
Treatment of essential hypertension not controlled with monotherapy
Who takes it
Adults · Children
Adult dose
Administer 1 tablet once daily with water, regardless of meals. It is recommended to take the medicine at the same time each day (e.g., in the morning), if possible. Before administering this medicine, it is recommended that the dose be adjusted using the individual components (S-amlodipine [amlodipine] or olmesartan medoxomil). However, if blood pressure is not controlled with monotherapy using either individual component, switching directly to this medicine may be considered. The maximum dose of this medicine is 5/40 milligrams. The maximum blood pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of 2 weeks or longer, taking the patient's blood pressure response into account. The recommended doses are as follows: - 2.5/20 milligrams: For patients whose blood pressure is not adequately controlled with monotherapy using S-amlodipine 2.5 milligrams (amlodipine 5 milligrams) or olmesartan medoxomil 20 milligrams. - 2.5/40 milligrams: For patients whose blood pressure is not adequately controlled with 2.5/20 milligrams. - 5/40 milligrams: For patients whose blood pressure is not adequately controlled with 2.5/40 milligrams. ∘ Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil in patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 milligrams once daily, and use of this medicine is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients on dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ∘ Patients with reduced effective intravascular volume: For patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to initiate treatment at a low dose while closely monitoring their condition. ∘ Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 milligrams once daily, and the maximum dose is 20 milligrams once daily. In patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics, blood pressure and renal function should be closely monitored. This medicine should not be administered to patients with severe hepatic impairment. (See section 2. Patients who should not receive this medicine under Precautions for Use.) ∘ Elderly patients: In general, initiate treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. In elderly patients, blood pressure should be monitored closely and more frequently.
Child dose
The safety and efficacy of this medicine have not been established in pediatric patients under 18 years of age.

Ingredients

Manufacturer
Anguk Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of essential hypertension not controlled with monotherapy

  • Essential hypertension
View approved original text

This medication is used when blood pressure is not adequately controlled due to essential hypertension. It effectively lowers blood pressure with 'S-Amlodipine (Amlodipine) or Olmesartan medoxomil' monotherapy, helping to prevent cardiovascular complications. Continuous use can stabilize blood pressure control.

How to take

Adult dose

Administer 1 tablet once daily with water, regardless of meals. It is recommended to take the medicine at the same time each day (e.g., in the morning), if possible. Before administering this medicine, it is recommended that the dose be adjusted using the individual components (S-amlodipine [amlodipine] or olmesartan medoxomil). However, if blood pressure is not controlled with monotherapy using either individual component, switching directly to this medicine may be considered. The maximum dose of this medicine is 5/40 milligrams. The maximum blood pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of 2 weeks or longer, taking the patient's blood pressure response into account. The recommended doses are as follows: - 2.5/20 milligrams: For patients whose blood pressure is not adequately controlled with monotherapy using S-amlodipine 2.5 milligrams (amlodipine 5 milligrams) or olmesartan medoxomil 20 milligrams. - 2.5/40 milligrams: For patients whose blood pressure is not adequately controlled with 2.5/20 milligrams. - 5/40 milligrams: For patients whose blood pressure is not adequately controlled with 2.5/40 milligrams. ∘ Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil in patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 milligrams once daily, and use of this medicine is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients on dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ∘ Patients with reduced effective intravascular volume: For patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to initiate treatment at a low dose while closely monitoring their condition. ∘ Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 milligrams once daily, and the maximum dose is 20 milligrams once daily. In patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics, blood pressure and renal function should be closely monitored. This medicine should not be administered to patients with severe hepatic impairment. (See section 2. Patients who should not receive this medicine under Precautions for Use.) ∘ Elderly patients: In general, initiate treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. In elderly patients, blood pressure should be monitored closely and more frequently.

Child dose

The safety and efficacy of this medicine have not been established in pediatric patients under 18 years of age.

Precautions

This medication can cause serious harm to the fetus and newborn if taken during pregnancy, especially in the second and third trimesters; therefore, it should never be used during pregnancy. If pregnancy is confirmed, discontinue use immediately and switch to another safe treatment. This medication is contraindicated in patients allergic to the active ingredients or related drugs, pregnant or breastfeeding women, patients with severe liver dysfunction, severe aortic stenosis, biliary obstruction, patients on dialysis, patients in shock, and certain diabetic patients. Patients with fluid or salt depletion may experience hypotension, so their condition should be closely monitored upon initial administration, and appropriate measures should be taken if hypotension occurs. Acute hypotension may rarely occur due to vasodilatory effects, necessitating caution in patients with aortic stenosis. Care should be taken when administering this medication to patients with severe heart disease, especially those with obstructive coronary artery disease or congestive heart failure. Patients with compromised kidney function may see worsening kidney function after taking this medication, so kidney function should be regularly monitored. Patients with liver dysfunction should also be monitored closely when taking this medication, and dosage adjustments may be necessary. During treatment, side effects such as dizziness, headache, hypotension, edema, gastrointestinal disturbances may arise, so patients should consult a physician if any abnormal symptoms occur. Older adults may have decreased kidney and liver function, so starting at a lower dosage and closely monitoring their condition is advised. This medication may interact with other drugs, so inform your doctor or pharmacist of any other medications you are taking. In cases of overdose, hypotension and heart function impairment may occur; therefore, seek immediate medical attention for appropriate treatment. This drug is not recommended for children as safety and efficacy in this age group have not been established.

Side effects

Drug hypersensitivity, hyperkalemia, decreased libido, dizziness, headache, orthostatic hypotension, drowsiness, paresthesia, sensory impairment, syncope, vertigo, palpitations, rapid pulse, hypotension, orthostatic hypotension, dyspnea, cough, nausea, vomiting, dyspepsia, diarrhea, constipation, dry mouth, abdominal pain, rash, urticaria, muscle tension, limb pain, low back pain, polyuria, erectile dysfunction, peripheral edema, edema, dependent edema, fatigue, weakness, facial edema, decreased serum potassium, increased serum creatinine, increased serum uric acid, increased gamma-glutamyl transferase, decreases in hemoglobin and hematocrit, low back pain, bronchitis, increased creatine phosphokinase, hematuria, hyperglycemia, hypertriglyceridemia, influenza-like symptoms, pharyngitis, rhinitis, sinusitis, weakness, angioedema, chronic malabsorption syndrome-like intestinal disease, intestinal vascular edema, rhabdomyolysis, acute kidney failure, hair loss, itching, autoimmune hepatitis, flushing, abdominal pain, nausea, gynecomastia, jaundice, elevated liver enzymes, leukopenia, thrombocytopenia, toxic epidermal necrolysis, significant hypotension, tachycardia, bradycardia

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent exposure to air or moisture, ideally at room temperature between 1 and 30 degrees Celsius. Storing it this way helps maintain its effectiveness for a longer period.

Appearance and packaging

Appearance

White round film-coated tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.